Dose HLA-B5, 7, 8, 27, and 51 Antigens Associated to Behcet's disease? A Study in Southwestern Iran

Author(s): Elham Rajaei, Mohammad T. Jalali, Seyed M. Sadegh Pezeshki, Hadi Rezaeeyan, Mahmood Maniati, Milad Elyasi, Zeinab D. Zayeri*

Journal Name: Current Rheumatology Reviews

Volume 16 , Issue 2 , 2020

Become EABM
Become Reviewer


Background: Behcet's disease is a potentially life threatening autoimmune disease with recurrent ulcers and unknown pathogenesis. Gender and human leukocyte antigen-B51 seem to have an effective role in the clinical features of the disease.

Objective: The aim of this study is to evaluate the frequency of HLA-B5, 7, 8, 27 and 51 in behçet's disease in southwestern Iranian patients who visited the rheumatology clinic and to find the association between these HLA types and the disease.

Methods: 63 patients with behcet's disease participated in this study and peripheral blood samples were collected from them. The expression of each HLA antigen was evaluated by standard lymphocytotoxicity technique.

Results: Compared to other studied antigens, the expression of HLA-B5 and HLA-B51 was more prevalent among our patients. According to the results, 25% and 21% of patients were positive for HLA-B5 and HLA-B51, respectively.

Conclusions: HLA-B5 and HLA-B51 are dominant positive HLA antigens among behcet's disease patients in the southwest of Iran; however, we cannot conclude that these antigens are valuable diagnostic or prognostic biomarkers due to our study limitations. We suggest studying the association between HLA-B antigens and inflammation severity in patients to determine the possible prognostic value of HLA-B antigens in Iranian population in the southwest and this region needs more studies in HLA subject among BD patients because of the frequency of BD to evaluate the value of HLA typing in BD prognosis.

Keywords: Behcet's disease, human leukocyte antigen, autoimmune disease, lymphocytotoxicity, HLA-B antigens, BD prognosis.

Gheita TA, Gheita HA, Kenawy SA. The potential of genetically guided treatment in Behçet’s disease. Pharmacogenomics 2016; 17(10): 1165-74.
[] [PMID: 27347725]
Direskeneli H. Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 2006; 45(12): 1461-5.
[] [PMID: 16998234]
Gheita TA, Raafat H, Khalil H, Hussein H. Serum level of APRIL/BLyS in Behçet’s disease patients: clinical significance in uveitis and disease activity. Mod Rheumatol 2013; 23(3): 542-6.
[] [PMID: 22752534]
Ryu HJ, Seo MR, Choi HJ, Baek HJ. Clinical phenotypes of Korean patients with Behcet disease according to gender, age at onset, and HLA-B51. Korean J Intern Med (Korean Assoc Intern Med) 2018; 33(5): 1025-31.
[] [PMID: 28073242]
Yazici H. The place of Behçet’s syndrome among the autoimmune diseases. Int Rev Immunol 1997; 14(1): 1-10.
[] [PMID: 9203022]
Davatchi F. Diagnosis/classification criteria for Behcet's disease Patholo-gy research international 2012; 2012
Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behçet disease: evolution of clinical manifestations. Medicine (Baltimore) 2011; 90(2): 125-32.
[] [PMID: 21358436]
Davatchi F, Shahram F, Nadji A. Performance of existing diagnosis/classification criteria for Behcet’s Disease in Iranian patients: analysis of 5666 patients and 2406 controls. APLAR J Rheumatol 2006; 9(3): 238-43.
Zeggini E, Ioannidis JP. Meta-analysis in genome-wide association studies. Pharmacogenomics 2009; 10(2): 191-201.
Kaya TI, Dur H, Tursen U, Gurler A. Association of class I HLA antigens with the clinical manifestations of Turkish patients with Behçet’s disease. Clin Exp Dermatol 2002; 27(6): 498-501.
[] [PMID: 12372094]
Ombrello MJ, Kirino Y, de Bakker PI, Gül A, Kastner DL, Remmers EF. Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proceedings of the National Academy of Sciences.
Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013; 45(2): 202-7.
[] [PMID: 23291587]
Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 2012; 11(10): 687-98.
[] [PMID: 22197900]
Gul A. Behcet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001; 19(5 Suppl 24): S6-S12.
Bodis G, Toth V, Schwarting A. Role of human leukocyte antigens (HLA) in autoimmune diseases HLA typing. Springer 2018; pp. 11-29.
Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet’s disease: from East to West. Clin Rheumatol 2010; 29(8): 823-33.
[] [PMID: 20354748]
Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behçet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008; 58(12): 3951-9.
[] [PMID: 19035493]
Davatchi F, Chams-Davatchi C, Shams H, et al. Adult Behcet’s disease in Iran: analysis of 6075 patients. Int J Rheum Dis 2016; 19(1): 95-103.
[] [PMID: 26258691]
Kurata R, Yonezawa T, Inoko H. Association Analysis of the Polymorphism of Human Leukocyte Antigen-A,-B and-E Gene with Behcet’s Disease in Japanese Cohort Using Sequencing-Based Typing Method. MOJ Immunol 2014; 1(3): 00013.
Gül A, Inanç M, Öcal L, Aral O, Koniçe M. Familial aggregation of Behçet’s disease in Turkey. Ann Rheum Dis 2000; 59(8): 622-5.
[] [PMID: 10913059]
Koné-Paut I, Geisler I, Wechsler B, et al. Familial aggregation in Behçet’s disease: high frequency in siblings and parents of pediatric probands. J Pediatr 1999; 135(1): 89-93.
[] [PMID: 10393610]
Greco A, De Virgilio A, Ralli M, et al. Behçet’s disease: New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 2018; 17(6): 567-75.
[] [PMID: 29631062]
Mizuki N, Ohno S. Immunogenetic studies of Behçet’s disease. Rev Rhum Engl Ed 1996; 63(7-8): 520-7.
[PMID: 8896070]
Radouane A, Oudghiri M, Chakib A. Naya A, Belhouari A, El Malki A, Eds. HLA-B*27 allele associated to Behçet’s disease and to anterior uveitis in Moroccan patients. Ann Biol Clin 2011; 69(4): 419-24.
Giza M, Koftori D, Chen L, Bowness P. Is Behçet’s disease a ‘class 1-opathy’? The role of HLA-B*51 in the pathogenesis of Behçet’s disease. Clin Exp Immunol 2018; 191(1): 11-8.
[] [PMID: 28898393]
Chajek-Shaul T, Pisanty S, Knobler H, et al. HLA-B51 may serve as an immunogenetic marker for a subgroup of patients with Behçet’s syndrome. Am J Med 1987; 83(4): 666-72.
[] [PMID: 3314492]
Takano M, Miyajima T, Kiuchi M, Ohmori K, Amemiya H, Yokoyama T, et al. Behçet disease and the HLA system. Tissue Antigens 1976; 8(2): 95-9.
[] [PMID: 968901]
Krause I, Molad Y, Weinberger A. Association of HLA-B5 with Clinical Expression and Severity of Behcet’s Disease in Israel. J Clin Rheumatol 1999; 5(3): 137-40.
[] [PMID: 19078372]
Soylu M, Ersöz TR, Erken E. The association between HLA B5 and ocular involvement in Behçet’s disease in southern Turkey. Acta Ophthalmol (Copenh) 1992; 70(6): 786-9.
[] [PMID: 1488888]
Shenavandeh S, Jahanshahi KA, Aflaki E, Tavassoli A. Frequency of HLA-B5, HLA-B51 and HLA-B27 in patients with idiopathic uveitis and Behçet’s disease: a case-control study. Reumatologia 2018; 56(2): 67-72.
[] [PMID: 29853720]
Lin Y-H, Tai T-Y, Pu C-Y, Hwang D-K, Chung Y-M, Chou Y-J. Epidemiology of behcet’s disease in Taiwan: A population-based study. Ophthalmic Epidemiol 2018; 25(4): 323-9.
[] [PMID: 29726724]

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [120 - 124]
Pages: 5
DOI: 10.2174/1573397115666190918153721
Price: $65

Article Metrics

PDF: 18